[email protected]

Research

Explore innovative research that is shaping the future of healthcare. Our work focuses on advancing medical knowledge, developing new treatments, and addressing critical health challenges globally. Join us in our mission to push the boundaries of science and improve patient care through groundbreaking research.

WE’ve work with

Sanofi

A randomized, Double-blind, Placebo-controlled, Parallel group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants with Non-Cystic Fibrosis Bronchiectasis

A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies

Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Boehringer Ingelheim Pharmaceuticals, Inc.

Proof of concept (proof of intervention principles) study assessing effects of Technology-
Assisted Respiratory Adherence prototype version 3 (a Digital Behavior Change Intervention, DBCI) on proximal clinical outcomes and mediators (psychological mediators, self-management behaviors) in individuals with COPD (IwCOPD)

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER™-ON)”

Aldeyra Therapeutics, Inc.

A Randomized, Double-Blind, Placebo-Controlled, Two-Period

Bristol-Myers Squibb Company

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis”

Abbott Diagnostics Scarborough, Inc.

Clinical Evaluation of the Investigational ID NOW TM cov1D-19 Assay

Horizon Therapeutics

A Phase 2b Randomized, Double-blind, Placebo controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis

Others

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

A randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinophilic asthma (EXHALE-4)

A multi-centre single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744.